Insider Selling: Kura Oncology (NASDAQ:KURA) SVP Sells 7,142 Shares of Stock

Kura Oncology, Inc. (NASDAQ:KURA) SVP Thomas James Doyle sold 7,142 shares of the stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total value of $60,421.32. Following the transaction, the senior vice president owned 145,167 shares of the company’s stock, valued at $1,228,112.82. This represents a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Thomas James Doyle also recently made the following trade(s):

• On Friday, November 14th, Thomas James Doyle sold 4,539 shares of Kura Oncology stock. The stock was sold at an average price of $11.18, for a total transaction of $50,746.02.

Kura Oncology Price Performance

Kura Oncology stock traded down $0.10 during mid-day trading on Tuesday, reaching $8.47. 1,149,028 shares of the company’s stock traded hands, compared to its average volume of 1,287,347. Kura Oncology, Inc. has a 12-month low of $5.41 and a 12-month high of $12.49. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 0.02. The stock has a 50 day moving average of $10.33 and a two-hundred day moving average of $9.05. The company has a market cap of $737.06 million, a price-to-earnings ratio of -3.42 and a beta of 0.25.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). The business had revenue of $20.75 million during the quarter, compared to analysts’ expectations of $17.48 million. Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%. Equities analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Analysts Set New Price Targets

KURA has been the topic of several analyst reports. Zacks Research cut Kura Oncology from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a research report on Thursday, January 22nd. JMP Securities restated a “market outperform” rating and set a $24.00 price target on shares of Kura Oncology in a report on Monday, October 20th. Wedbush restated an “outperform” rating and issued a $38.00 price target (up from $36.00) on shares of Kura Oncology in a research report on Friday, November 14th. Finally, Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a research report on Friday, December 5th. Nine research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $28.00.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Kura Oncology by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock valued at $333,000 after acquiring an additional 2,977 shares during the period. Strs Ohio bought a new stake in shares of Kura Oncology during the first quarter worth $143,000. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Kura Oncology by 169.3% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 56,912 shares of the company’s stock valued at $334,000 after purchasing an additional 35,779 shares during the period. KLP Kapitalforvaltning AS boosted its stake in shares of Kura Oncology by 179.4% during the second quarter. KLP Kapitalforvaltning AS now owns 19,000 shares of the company’s stock valued at $110,000 after purchasing an additional 12,200 shares during the period. Finally, CWM LLC grew its holdings in shares of Kura Oncology by 46.0% in the second quarter. CWM LLC now owns 41,406 shares of the company’s stock worth $239,000 after purchasing an additional 13,053 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.